Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
GLR2037 in Advanced Prostate Carcinoma: NCT07468396 Clinical Landscape Report 2026
16 October 2026
NCT07468396 clinical landscape for Advanced Prostate Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zanidatamab in HER2 Positive Gastroesophageal Adenocarcinoma: NCT07477444 Clinical Landscape Report 2026
16 October 2026
NCT07477444 clinical landscape for HER2 Positive Gastroesophageal Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developme…
9 min read
SC-101(siRNA) in Resistant hypertension: NCT07483372 Clinical Landscape Report 2026
16 October 2026
NCT07483372 clinical landscape for Resistant hypertension: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dapagliflozin in Kidney Failure, Chronic: NCT07491042 Clinical Landscape Report 2026
16 October 2026
NCT07491042 clinical landscape for Kidney Failure, Chronic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Desidustat in Chronic Kidney Diseases: CTRI/2026/03/106748 Clinical Landscape Report 2026
16 October 2026
CTRI/2026/03/106748 clinical landscape for Chronic Kidney Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Xaluritamig in Metastatic castration-resistant prostate cancer: NCT07493512 Clinical Landscape Report 2026
16 October 2026
NCT07493512 clinical landscape for Metastatic castration-resistant prostate cancer: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
Retlirafusp alfa in Locally Advanced Gastroesophageal Junction Adenocarcinoma: NCT07493382 Clinical Landscape Report 2026
16 October 2026
NCT07493382 clinical landscape for Locally Advanced Gastroesophageal Junction Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context a…
9 min read
Indocyanine Green in stomach adenocarcinoma: CTRI/2026/03/106911 Clinical Landscape Report 2026
16 October 2026
CTRI/2026/03/106911 clinical landscape for stomach adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iparomlimab/Tuvonralimab in HER2 negative Gastroesophageal Junction Adenocarcinoma: NCT07502027 Clinical Landscape Report 2026
16 October 2026
NCT07502027 clinical landscape for HER2 negative Gastroesophageal Junction Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and…
9 min read
Rosuvastatin Calcium in Chronic Kidney Diseases: NCT07515339 Clinical Landscape Report 2026
16 October 2026
NCT07515339 clinical landscape for Chronic Kidney Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TROP2-CAR-NK(M.D. Anderson Cancer Center) in Secondary malignant neoplasm of peritoneum: NCT07509008 Clinical Landscape Report 2026
16 October 2026
NCT07509008 clinical landscape for Secondary malignant neoplasm of peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Durvalumab in Gastroesophageal junction adenocarcinoma: NCT07507968 Clinical Landscape Report 2026
16 October 2026
NCT07507968 clinical landscape for Gastroesophageal junction adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development wh…